New Obesity Drug Zepbound Approved by FDA After Rival Wegovy

Benzinga

The FDA approved Eli Lilly's potent obesity drug tirzepatide, which will be marketed under the name Zepbound. This approval makes it the second drug in its class approved for obesity treatment, after Novo Nordisk's Wegovy. In trials, Zepbound achieved weight loss of up to 21% of body weight, higher than the 15% achieved by Wegovy. Both target the GLP-1 and GIP hormones. Lilly expects Zepbound to be available in US pharmacies after Thanksgiving. It will be priced the same as Mounjaro at over $1,000 per month, around 20% lower than Wegovy. Lilly is doubling its manufacturing capacity to meet demand.

Transcript

00:00 It's Benzinga and here's what's on the block.

00:02 The FDA approved Eli Lilly's potent obesity drug, Terzepatide, which will be marketed

00:07 under the name ZepBound.

00:09 This approval makes it the second drug in its class approved for obesity treatment after

00:13 Novo Nordisk's Wegovy.

00:16 In trials, ZepBound achieved weight loss of up to 21% at body weight, higher than the

00:20 15% achieved by Wegovy.

00:23 Both targeted the GLP-1 and GIP hormones.

00:26 Lilly expects ZepBound to be available in the US pharmacies after Thanksgiving.

00:30 It will be priced the same as Munjaro at over $1,000 per month, around 20% lower than Wegovy.

00:37 Lilly is doubling its manufacturing capacity to meet demand.

00:40 For all things money, visit Benzinga.com.

00:42 [BLANK_AUDIO]

Category

Transcript

Comments

Recommended